Prosecution Insights
Prosecution Insights
Tech Center 3700 • Art Units: 1618 3797
This examiner grants 41% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18411055 | COMPOUND AND LABELED BIOLOGICAL SUBSTANCE USING THE SAME | Non-Final OA | FUJIFILM Corporation |
| 19405474 | SUSPENSION CONTAINING RADIOACTIVE MICROSPHERES, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Final Rejection | Chengdu Shetai Medical Technology Co., Ltd. |
| 19272744 | NANO-PARTICLES OF MENAQUINONE-9 AND METHODS OF TREATMENT | Non-Final OA | Epizon, Inc. |
| 18554403 | COMPOUNDS AND METHODS FOR THERANOSTIC TARGETING OF PARP ACTIVITY | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17997299 | METHODS FOR RADIOLABELING PSMA BINDING LIGANDS AND THEIR KITS | Non-Final OA | Novartis AG |
| 17997295 | METHODS FOR RADIOLABELLING PSMA BINDING LIGANDS AND THEIR KITS | Non-Final OA | Novartis AG |
| 17264222 | COMPETITIVE PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) BINDING AGENTS FOR REDUCTION OF NON-TARGET ORGAN UPTAKE OF RADIOLABELED PSMA INHIBITORS FOR PSMA POSITIVE TUMOR IMAGING AND RADIOPHARMACEUTICAL THERAPY | Non-Final OA | The Johns Hopkins University |
| 17919848 | Fluorinated Derivatives of Gabapentin and Methods of Use Thereof | Non-Final OA | The General Hospital Corporation |
| 17725271 | BIOREDUCTIVELY-ACTIVATED COMPOUNDS, THEIR PRODRUGS, RADIOPHARMACEUTICALS, THE COMPOSITIONS, AND THEIR APPLICATIONS IN MULTIMODAL THERANOSTIC MANAGEMENT OF HYPOXIA DISEASES INCLUDING CANCER | Final Rejection | The Governors of the University of Alberta |
| 17705781 | Multi-Enzyme Nanoparticle-Assisted Stable Isotope Incorporation Into Small Molecules by Channeling | Final Rejection | The Government of the United States of America, as represented by the Secretary of the Navy |
| 18288667 | CANCER-SPECIFIC POLYPEPTIDE AND USE THEREOF | Final Rejection | THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 18247427 | METHODS AND COMPOSITIONS FOR SYNERGISTIC UPTAKE AND RETENTION OF SMALL MOLECULE LIGANDS | Non-Final OA | CORNELL UNIVERSITY |
| 18044356 | METHOD FOR TREATING ACUTE MYELOID LEUKEMIA USING VENETOCLAX IN CONJUNCTION WITH LINTUZUMAB-AC225 | Final Rejection | ACTINIUM PHARMACEUTICALS, INC. |
| 18632964 | Imaging Agents | Final Rejection | UCB Biopharma SRL |
| 18569650 | Intratumoral Alpha-Emitter Radiation in Combination with Immune Checkpoint Regulators | Non-Final OA | ALPHA TAU MEDICAL LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy